Senolytic drugs reduce COVID-19 symptoms in mice, study shows
In pre-clinical studies, senolytic drugs were found to reduce inflammation and death from COVID-19 in older mice.
List view / Grid view
In pre-clinical studies, senolytic drugs were found to reduce inflammation and death from COVID-19 in older mice.
Scientists have found four clinically approved drugs and nine compounds with the potential to be repurposed as therapeutics for COVID-19.
The experimental drug TEMPOL has demonstrated antiviral activity against COVID-19 in a pre-clinical study in cell cultures.
A new high-throughput screening platform has been used to identify two compounds with antiviral activity against the Nipah and Hendra viruses.
A synthetic antiviral named R327 has shown promise in initial tests against SARS-CoV-2 and is now advancing to the next stage of in vitro studies.
Dr Sotirios Karathanasis discusses the history of cannabis as a treatment and delves into the process of turning plant-based medicines into clinically proven drugs.
Researchers have developed a set of compounds designed to stop the malaria parasite being able to burst out of red blood cells and replicate.
Two screening techniques were used by researchers to find anticancer compounds that target the aryl hydrocarbon receptor.
An airway-on-a-chip has been used to show that amodiaquine inhibits SARS-CoV-2 infection, making it a potential COVID-19 therapeutic.
After screening 4,500 compounds using induced pluripotent stem cells, researchers have identified one lead that could treat pulmonary arterial hypertension.
The fat molecule avocatin B, found in avocados, was shown to inhibit VLCAD, an enzyme vital for leukaemia cell metabolism.
Four hepatitis C drugs have demonstrated promise as boosters to increase the efficacy of remdesivir against SARS-CoV-2 by as much as tenfold.
Having synthesised the curcusone D compound, researchers demonstrated its promise as the first BRAT1 inhibitor, making it a potential cancer therapy.
Dr James Woody discusses off-patent indications for anti-TNF to address unmet patient needs in pain, inflammation and beyond.
Dr Praveen Prathapan explains why broad-spectrum therapeutics need to be identified to provide a safety net against pandemics, including COVID-19.